Abstract #1165
Validation of T2 mapping for treatment response monitoring in longitudinal multi-center clinical trials
Petra J van Houdt 1 , Harsh K Agarwal 2,3 , Laurens B van Buuren 1 , Marko Ivancevic 4 , Sren Haack 5 , Jesper Folsted Kallehauge 6 , Peter L Choyke 3 , and Uulke A van der Heide 1
1
Radiation Oncology, the Netherlands Cancer
Institute, Amsterdam, Netherlands,
2
Philips
Research NA, Briarcliff Manor, MD, United States,
3
National
Cancer Institute, National Institutes of Health,
Bethesda, NY, United States,
4
Philips
Healthcare, Best, Netherlands,
5
Clinical
Engineering, Aarhus University Hospital, Aarhus,
Denmark,
6
Medical
Physics, Aarhus University Hospital, Aarhus, Denmark
T2 is proposed as a biomarker for response monitoring of
patients with prostate cancer treated with radiotherapy.
A key requirement in multi-center longitudinal studies
is good reproducibility over multiple visits. The
purpose of this study was to establish the inter- and
intra-center reproducibility of T2 maps. Phantom
measurements were performed on three platforms, showing
that the differences in T2 values within and between
platforms were smaller than 5%. Average difference in T2
values of volunteers between two visits was -1.5 +/-
9.5%. This work demonstrates that T2 mapping is suitable
for use in multi-center, longitudinal trials in prostate
cancer patients.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
